Developing an Opportune Future in Healthcare
Neuroscience
Oncology
Alercell, Inc., a Montana company is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients worldwide. Alercell is focused on two segments: Oncology & Neuroscience
Oncology
Neuroscience
Oncology
Alercell Oncology launched in January 2023 Lena Q51 the very first Leukemia diagnostic test able to detect up to 51 genes mutations. Genes mutations in Leukemia is a significant biomarker indication of the disease.
Alercell Oncology will launch soon Lena S1, a Lung cancer early diagnostic test based on DNA Methylation
Neuroscience
Neuroscience
Neuroscience
Alercell Neuroscience aims to create a nanoparticle neural interface for recording and controlling brain activity with the ultimate goal to find solutions for neurodegenerative diseases such as dementia or Alzheimer.